Anzeige
Mehr »
Mittwoch, 09.09.2026 - Börsentäglich über 12.000 News

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

Aktuelle News von FiercePharma

  • 24 h
  • letzte 200 News
ZeitAktuelle Nachrichten
31.08.B. Braun adds to a string of IV solution recalls in US
31.08.Jazz's Ziihera secures 2nd survival win to solidify its HER2-positive stomach cancer status
29.08.ESC: AstraZeneca, Ionis' Wainua post-mortem throws water on silencer-plus-stabilizer approach in ATTR-CM
28.08.Lilly scores Novo-pressuring Mounjaro expansion to curb heart risks in diabetes patients
28.08.MrBeast, Snapchat, AI and more: Pharma marketing's pulse check
28.08.Biogen enlists lupus patient advocate to share social media story of resilience
28.08.Stephen Farquhar takes over as CEO of Publicis Health Media
28.08.Omnicom PR consultancy injects new leadership into pharma push
27.08.BMS splashes out $173M to build 2nd radiopharmaceutical plant in Indiana
27.08.As RevMed preps for 'historic' pancreatic cancer launch, questions linger on the ground
27.08.PhRMA's Medicare price negotiation suit rebuffed in latest blow to industry IRA challenge
27.08.Amgen, AstraZeneca's Tezspire lands phase 3 eosinophilic esophagitis win, turning up heat on Dupixent
27.08.Artis BioSolutions expands synthetic DNA, mRNA production with Spanish facility
27.08.Trump set to reveal MFN pricing deals with mid-sized companies: report
26.08.FDA greenlights Revolution Medicines' pancreatic cancer gamechanger
26.08.Akeso CEO looks beyond lung cancer with biliary tract win, counters ivonescimab debate
26.08.Baxter issues recall of 2 products after particulate concerns resurface
26.08.With Trump's nominee pick in, FDA weighs new deputy commissioner posts: report
25.08.NAD reaches split decision on hair ad row between Kenvue and Hims & Hers
25.08.McKesson strikes $2.25B deal to snap up Precision Medicine Group
25.08.Bausch + Lomb flops in ph. 2 with Xiidra and Miebo but advances combo to ph. 3
25.08.Johnson & Johnson scores 1st FDA label expansion for Imaavy
24.08.Merck, AstraZeneca lawsuits against Medicare price negotiations swatted down
24.08.Hansa lays groundwork for Nasdaq debut ahead of US kidney transplant drug verdict
24.08.After Trump order, RFK Jr. seeks input on US pediatric vaccine recommendations